Bavarian Nordic A/S (BVNRY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Henrik Juuel M.Sc.
|
CFO & Executive VP | 1.79M | -- | 1965 |
|
Ms. Tarja Stenvall
|
President & CEO | -- | -- | -- |
|
Mr. Russell Thirsk M.Sc.
|
Executive VP & COO | -- | -- | 1968 |
|
Ms. Nicole Seroff
|
Vice President Corporate Communications | -- | -- | -- |
|
Mr. Jean-Christophe May M.B.A., Pharm.D.
|
Executive VP & Chief Commercial Officer | -- | -- | 1967 |
Bavarian Nordic A/S
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1,906
Description
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
April 6, 2020 at 12:00 AM UTC
Dividend Date
March 27, 2020 at 12:00 AM UTC
Ex-Dividend Date
